Compare AVLN & LOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVLN | LOB |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2026 | 2014 |
| Metric | AVLN | LOB |
|---|---|---|
| Price | $29.89 | $34.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $61.80 | $40.50 |
| AVG Volume (30 Days) | ★ 432.2K | 274.0K |
| Earning Date | 11-12-2026 | 10-21-2026 |
| Dividend Yield | N/A | ★ 0.35% |
| EPS Growth | N/A | ★ 31.95 |
| EPS | N/A | ★ 1.86 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.98 |
| Revenue Next Year | N/A | $14.96 |
| P/E Ratio | ★ N/A | $18.55 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.24 | $29.36 |
| 52 Week High | $40.17 | $44.53 |
| Indicator | AVLN | LOB |
|---|---|---|
| Relative Strength Index (RSI) | 58.89 | 47.67 |
| Support Level | $25.86 | $33.56 |
| Resistance Level | $33.32 | $36.68 |
| Average True Range (ATR) | 1.93 | 1.04 |
| MACD | 0.67 | 0.12 |
| Stochastic Oscillator | 74.04 | 46.86 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.